Trial Profile
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Aspirin; Prasugrel
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Pharmacodynamics
- Acronyms HEIGHTEN
- 20 Nov 2014 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 20 Nov 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 20 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.